Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: YMAS THER

Market Cap 391M 337M 310M 291M 546M 37.21B 552M 3.68B 1.43B 18.09B 1.47B 1.44B 62.49B P/E Ratio 2023
-13.9x
P/E Ratio 2024 -11.7x
Enterprise Value 325M 280M 258M 241M 454M 30.89B 458M 3.05B 1.19B 15.02B 1.22B 1.19B 51.88B EV / Sales 2023
2,597,077x
EV / Sales 2024 3,242,111x
Free-Float
-
Yield 2023 *
-
Yield 2024 -
1 year 3.9
Extreme 3.9
8.61
3 years 3.55
Extreme 3.55
20.9
5 years 2.7
Extreme 2.7
39.82
10 years 2.7
Extreme 2.7
55.22
Manager TitleAgeSince
President - 16/09/2025
Chief Tech/Sci/R&D Officer 75 01/01/2016
Treasurer - 16/09/2025
Director TitleAgeSince
Director/Board Member - 16/09/2025
Director/Board Member - 16/09/2025
Director/Board Member - 16/09/2025
Date Insider Type Main position Quantity % Market Cap.
16/09/25
Sofinnova Investments, Inc.
TenderCompany 2,194,278 4.8991%
16/09/25Issuer sale

Chief Financial Officer

343,100 0.7660%
16/09/25Issuer sale

Director

170,850 0.3815%

Financials

2023 2024
Net sales 84.82 73.01 67.25 63.06 118.43 8.07K 119.71 796.79 309.77 3.92K 318.28 311.52 13.55K 87.68 75.48 69.53 65.19 122.43 8.34K 123.75 823.72 320.23 4.05K 329.04 322.05 14.01K
Net income -21.43M -18.44M -16.99M -15.93M -29.92M -2.04B -30.24M -201M -78.25M -991M -80.4M -78.7M -3.42B -29.67M -25.54M -23.52M -22.06M -41.42M -2.82B -41.87M -279M -108M -1.37B -111M -109M -4.74B
Net Debt -77.22M -66.47M -61.23M -57.41M -108M -7.34B -109M -725M -282M -3.57B -290M -284M -12.33B -66.41M -57.17M -52.66M -49.38M -92.73M -6.32B -93.73M -624M -243M -3.07B -249M -244M -10.61B
Logo YMAS THER
Y-mAbs Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of radioimmunotherapy and antibody-based therapeutic cancer products. Its technologies include its investigational Self-Assembly DisAssembly (SADA) Pretargeted Radioimmunotherapy Platform and bispecific antibodies generated using the Y-BiClone platform. Its advanced product pipeline includes the anti-GD2 therapy DANYELZA (naxitamab-gqgk), a food and drug administration (FDA)-approved treatment for patients with relapsed or refractory neuroblastoma in the bone or bone marrow after a partial response, minor response or stable disease to prior therapy. DANYELZA is a humanized immunoglobulin G, subtype 1k (IgG1k), monoclonal antibody (mAb), that targets ganglioside GD2, which is expressed in various neuroectoderm derived tumors and sarcomas. Omburtamab targets B7-H3, an immune checkpoint molecule that is expressed in tumor cells of several cancer types.
Employees
104
Sector
-
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
B
  1. Stock Market
  2. Stocks
  3. YMAB Stock
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!